title: Results of photoprovocation and field studies on the efficacy of a novel topically applied antioxidant in polymorphous light eruption.
abstract: BACKGROUND
  UVA-induced photooxidation is considered to play an essential role in the pathogenesis of polymorphous light eruption (PLE), and topical pretreatment of skin with alpha-glucosylrutin (AGR), a potent plant-derived antioxidant, has been shown to significantly suppress photoprovoked PLE eruption.
  
  
  OBJECTIVE
  In order to further elucidate the optimum pretreatment regimen and to investigate the efficacy and skin compatibility of topical preparations containing AGR under field conditions, two controlled clinical studies were conducted in PLE patients.
  
  
  METHODS
  In the first study, photoprovocation of PLE was performed in 20 patients, using UVA irradiation (4 x 60-100 J/cm(2)), applied to four test sites at the individual areas of predilection. One site served as an untreated control. The remaining three sites received treatment with a SPF 15 sunscreen containing 0.25% AGR (Eucerin Gel Cream Phase 2) 30 minutes before irradiation. Two of these sites were additionally pretreated with the corresponding AGR-containing vehicle (Eucerin Gel Cream Phase 1) twice daily for 3 and 7 days, respectively. The second study was conducted as a controlled in-use-test in patients with PLE (n = 27) or acne aestivalis (n = 3), who had suffered from the disease during their last year's vacation. They were educated to apply the pre-sun preparation to the formerly affected skin areas twice daily for 1 week before their planned vacation and to use the SPF 15 sunscreen 30 minutes before each vacation sun exposure. Symptoms were recorded in patients' diaries throughout the vacation and documented by a physician after their return.
  
  
  RESULTS
  In the first study, protection of skin with the SPF 15 sunscreen alone led to a significant prevention of PLE symptoms, especially itch, compared with the control area. Pretreatment further reduced the severity of PLE significantly and led to total prevention in 19 patients. In the second study, whereas 92.6% had reported severe and 7.4% mild PLE in the last year, there were currently only 7.4% severe cases, with 25.9% mild and 29.6% questionable cases; 37% had no symptoms at all. Also, two out of three acne aestivalis patients had diminished symptoms after treatment.
  
  
  CONCLUSIONS
  The results confirm the prophylactic efficacy of the antioxidant AGR in PLE, applied as SPF 15 sunscreen alone or additionally to pretreatment with a corresponding pre-sun preparation, and also show an effect in acne aestivalis patients.
authors.affiliation: Beiersdorf AG, Hamburg, Germany. rippkef@hamburg.beiersdorf.com
authors.forename: F
authors.initials: F
authors.lastname: Rippke
authors.forename: G
authors.initials: G
authors.lastname: Wendt
authors.forename: K
authors.initials: K
authors.lastname: Bohnsack
authors.forename: A
authors.initials: A
authors.lastname: Dörschner
authors.forename: F
authors.initials: F
authors.lastname: Stäb
authors.forename: E
authors.initials: E
authors.lastname: Hölzle
authors.forename: I
authors.initials: I
authors.lastname: Moll
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000975:Antioxidants / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005782:Gels; D006801:Humans; D008297:Male; D014677:Pharmaceutical Vehicles; D010787:Photosensitivity Disorders / Q000517:prevention & control*; D013473:Sunscreening Agents / Q000627:therapeutic use; D024505:Tocopherols; D016896:Treatment Outcome; D014466:Ultraviolet Rays / Q000009:adverse effects; D024502:alpha-Tocopherol / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000975:Antioxidants; D005782:Gels; D014677:Pharmaceutical Vehicles; D013473:Sunscreening Agents; D024502:alpha-Tocopherol; D024505:Tocopherols